Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma

World Journal of Gastroenterology

Volumn 16, Issue 37, 2010, Pages 4697-4703

  Leelawat, Kawin ^a,b   Narong, DegreesSirdegreesiluck ^a   Wannaprasert, Jerasak ^a,b   Ratanashu ek, Thawee ^a,b  

^a RAJAVITHI HOSPITAL   (Thailand)

^b RANGSIT UNIVERSITY   (Thailand)

Author keywords

Carbohydrate antigen 19 9; Cholangiocar cinoma; Matrix metalloproteinase 7; Sensitivity; Specificity; Tumor marker

Indexed keywords

CA 19-9 ANTIGEN; MATRILYSIN;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BILE DUCT CARCINOMA; BILIARY TRACT DISEASE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OBSTRUCTIVE JAUNDICE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

EID: 77957819926     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i37.4697     Document Type: Article

References (30)

1. Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol 2008; 24: 349-356
2. Bridgewater J, Imber C. New advances in the management of biliary tract cancer. HPB (Oxford) 2007; 9: 104-111
3. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis 2008; 12: 131-150, ix
4. Byrnes V, Afdhal N. Cholangiocarcinoma of the Hepatic Hilum (Klatskin Tumor). Curr Treat Options Gastroenterol 2002; 5: 87-94
5. Furmanczyk PS, Grieco VS, Agoff SN. Biliary brush cytology and the detection of cholangiocarcinoma in primary scleros-ing cholangitis: evaluation of specifc cytomorphologic features and CA19-9 levels. Am J Clin Pathol 2005; 124: 355-360
6. Leelawat K, Sakchinabut S, Narong S, Wannaprasert J. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroen-terol 2009; 9: 30
7. Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE Jr. Diagnostic role of serum CA 19-9 for chol-angiocarcinoma in patients with primary sclerosing cholan-gitis. Mayo Clin Proc 1993; 68: 874-879
8. Leelawat K, Leelawat S, Ratanachu-Ek T, Trubwongchareon S, Wannaprasert J, Tripongkaruna S, Chantawibul S, Te-paksorn P. Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients. World J Gastroenterol 2006; 12: 4195-4198
9. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcino-ma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 204-207
10. Ong SL, Sachdeva A, Garcea G, Gravante G, Metcalfe MS, Lloyd DM, Berry DP, Dennison AR. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci 2008; 53: 3213-3217
11. Principe A, Del Gaudio M, Grazi GL, Paolucci U, Cavallari A. Mirizzi syndrome with cholecysto-choledocal fistula with a high CA19-9 level mimicking biliary malignancies: a case report. Hepatogastroenterology 2003; 50: 1259-1262
12. Itatsu K, Zen Y, Yamaguchi J, Ohira S, Ishikawa A, Ikeda H, Sato Y, Harada K, Sasaki M, Sasaki M, Sakamoto H, Nagino M, Nimura Y, Ohta T, Nakanuma Y. Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts. Hum Pathol 2008; 39: 710-719
13. Itatsu K, Zen Y, Ohira S, Ishikawa A, Sato Y, Harada K, Ikeda H, Sasaki M, Nimura Y, Nakanuma Y. Immunohis-tochemical analysis of the progression of fat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogen-esis in hepatolithiasis. Liver Int 2007; 27: 1174-1184
14. Miwa S, Miyagawa S, Soeda J, Kawasaki S. Matrix metal-loproteinase-7 expression and biologic aggressiveness of cholangio cellular carcinoma. Cancer 2002; 94: 428-434
15. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008; 100: 1432-1438
16. Bossuyt PM, Reitsma JB. The STARD initiative. Lancet 2003; 361: 71
17. Bruns DE. The STARD initiative and the reporting of studies of diagnostic accuracy. Clin Chem 2003; 49: 19-20
18. Bossuyt PM. STARD statement: still room for improvement in the reporting of diagnostic accuracy studies. Radiology 2008; 248: 713-714
19. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843
20. Huh JW, Kim DS, Oh YM, Shim TS, Lim CM, Lee SD, Koh Y, Kim WS, Kim WD, Kim KR. Is metalloproteinase-7 specific for idiopathic pulmonary fibrosis? Chest 2008; 133: 1101-1106
21. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 2006; 231: 20-27
22. Noë V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001; 114: 111-118
23. Yamamoto H, Adachi Y, Itoh F, Iku S, Matsuno K, Kusano M, Arimura Y, Endo T, Hinoda Y, Hosokawa M, Imai K. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 1999; 59: 3313-3316
24. Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 1999; 45: 252-258
25. Yamamoto H, Iku S, Adachi Y, Imsumran A, Taniguchi H, Nosho K, Min Y, Horiuchi S, Yoshida M, Itoh F, Imai K. Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. J Pathol 2003; 199: 176-184
26. Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004; 10: 2832-2845
27. Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW, McIntosh MW, Brown PO, Nelson BH, Urban N. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One 2008; 3: e2633
28. Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, Mármol M, Gallardo E, Maria Augé J, Longarón R, Martínez-Fernandez A, Molina R, Castells A, Gascón P. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer 2007; 121: 1066-1071
29. Yeh YC, Sheu BS, Cheng HC, Wang YL, Yang HB, Wu JJ. Elevated serum matrix metalloproteinase-3 and -7 in H. pylori-related gastric cancer can be biomarkers correlating with a poor survival. Dig Dis Sci 2010; 55: 1649-1657
30. Biesheuvel CJ, Vergouwe Y, Oudega R, Hoes AW, Grobbee DE, Moons KG. Advantages of the nested case-control design in diagnostic research. BMC Med Res Methodol 2008; 8: 48